Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | NPM1 | P06748 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120440 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL780275 | 0.92 | ALDH1A1 (0.52) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL1932985 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL30775025 | 0.79 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2C19PIK3R1PIK3CA | |
| SCHEMBL629503 | 0.79 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2C19PIK3R1PIK3CA | |
| SCHEMBL26919701 | 0.79 | HTT (0.44) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL1600169 | 0.76 | BACE1 (0.57) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL797784 | 0.76 | HTT (0.41) | HTTCYP1A2CYP2C19PABPC1ALK | |
| SCHEMBL15150158 | 0.76 | HTT (0.41) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL1639504 | 0.76 | HTT (0.41) | ALDH1A1HTTCYP1A2CYP2C19PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865942-A | Quinoxaline derivative and application thereof in preparation of medicines for treating non-small cell lung cancer | 四川轻化工大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2024057332-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ERDAFITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS & POLYMORPHS THEREOF | NATCO PHARMA LIMITED (IN) | 2024-03-21 | — | — | WO | claimed |
| CN-115108926-B | Intermediate compound for preparing erdasatinib and preparation method | 上海工程技术大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115108926-A | Intermediate compound for preparing erdastinib and preparation method | 上海工程技术大学 | 2022-09-27 | — | — | CN | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CYPRALIS LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| WO-2025149622-A1 | WNK1 INHIBITORS | DANIA THERAPEUTICS APS (DK) | 2025-07-17 | — | — | WO | disclosed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-5696119-A | SOLID TUMORS, LEUKEMIA | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1994013647-A1 | (2-QUINOXALINYLOXY)PHENOXYPROPANOIC ACIDS AND RELATED DERIVATIVES AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | ALDH1A1 2837/4885HTT 3797/4885CYP1A2 656/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | ALDH1A1 1346/4885HTT 2715/4885CYP1A2 3740/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | ALDH1A1 1471/4885HTT 517/4885CYP1A2 3980/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | ALDH1A1 1006/4885HTT 4222/4885CYP1A2 2185/4885 |
| US-20250243219-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CASP3, TNNC1, BAD | ALDH1A1 2662/4885HTT 504/4885CYP1A2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.